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Abstract
Background: The complexity of metabolic networks can make the origin and impact of changes in central metabolism
occurring during diseases difficult to understand. Computer simulations can help unravel this complexity, and progress
has advanced in genome-scale metabolic models. However, many models produce unrealistic results when challenged
to simulate abnormal metabolism as they include incorrect specification and localisation of reactions and transport steps,
incorrect reaction parameters, and confounding of prosthetic groups and free metabolites in reactions. Other common
drawbacks are due to their scale, making them difficult to parameterise and simulation results hard to interpret. Therefore,
it remains important to develop smaller, manually curated models.
Results: We present MitoCore, a manually curated constraint-based computer model of human metabolism that
incorporates the complexity of central metabolism and simulates this metabolism successfully under normal and
abnormal physiological conditions, including hypoxia and mitochondrial diseases. MitoCore describes 324 metabolic
reactions, 83 transport steps between mitochondrion and cytosol, and 74 metabolite inputs and outputs through the
plasma membrane, to produce a model of manageable scale for easy interpretation of results. Its key innovations
include a more accurate partitioning of metabolism between cytosol and mitochondrial matrix; better modelling of
connecting transport steps; differentiation of prosthetic groups and free co-factors in reactions; and a new representation
of the respiratory chain and the proton motive force. MitoCore’s default parameters simulate normal cardiomyocyte
metabolism, and to improve usability and allow comparison with other models and types of analysis, its reactions and
metabolites have extensive annotation, and cross-reference identifiers from Virtual Metabolic Human database and KEGG.
These innovations—including over 100 reactions absent or modified from Recon 2—are necessary to model central
metabolism more accurately.
Conclusion: We anticipate MitoCore as a research tool for scientists, from experimentalists looking to interpret
their data and test hypotheses, to experienced modellers predicting the consequences of disease or using
computationally intensive methods that are infeasible with larger models, as well as a teaching tool for those
new to modelling and needing a small, manageable model on which to learn and experiment.
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Background
Human central metabolism is a large and complex
system under sensitive homeostatic control, and its
disturbance is causative or associated with many diseases
and responses to toxins. However, it is often difficult to
relate more than a handful of these changes to their
underlying origin or their down-stream impact, due to
the highly connected nature of the reactions of central
metabolism. Computer models are widely accepted in
many fields as a tool to incorporate complexity and
simulate changes, allowing predictions to be made and
providing a unifying framework to interpret empirical
data, especially from large, noisy and incomplete data
sets. Yet modelling is treated with scepticism by many
biomedical researchers despite their potential broad
utility [1]. Simple models of enzyme kinetics (using the
assumptions of Henri-Michaelis-Menten kinetics [2]) are
familiar to biomedical scientists, but are impractical for
simulations of central metabolism due to every reaction
needing parameterisation, alongside the computational
expense of solving the large set of differential equations.
However, constraint-based models of metabolism used
in conjunction with methods such as flux balance ana-
lysis [3] are particularly useful for simulating metabolic
changes in large metabolic networks as they can incorp-
orate flexibility, do not require kinetic parameters and
are computationally inexpensive. Many genome-scale
constraint-based models [4–10] have covered central
metabolism and used successfully to model diseases [11,
12]. But these models do not simulate the realistic
production rate of ATP (with the recent exception of
Recon 2.2 [10]), a crucial element of modelling central
metabolism. Furthermore, the interpretation of simula-
tion results from thousands of reactions is difficult
(especially for new-comers). In addition, attempts to
simulate diseases can result in the prediction of physio-
logically improbable reaction fluxes due to erroneous
“short-circuits” and energy-generating cycles [13]. These
are caused by several common problems including:
incorrect parameters for directionality constraints, the
assignment of reactions to the wrong cellular compart-
ments, or inaccurate representations of pathways,
enzymes, transport steps, prosthetic groups and metabo-
lites. These errors can introduce unrealistic bypasses and
shuttles that appear to compensate for a disease state.
For example, proton-coupled mitochondrial transporters
running in reverse and thus pumping protons that
contribute to ATP generation by the mitochondrial ATP
synthase, and the confounding of free co-factors with
prosthetic groups, especially the flavin adenine dinucleo-
tide of mitochondrial succinate dehydrogenase (SDH)
and electron-transferring flavoprotein (ETF), leading to
incorrect electron transport between isolated complexes
mediated by bound FAD/FADH. These problems are
common in genome-scale models that include an initial
auto-generation of the reaction network from databases
that can include incomplete or incorrect annotation.
These issues are particularly acute for modelling
mitochondrial metabolism and metabolite transport, as
all the current genome-scale models neglect the
electrical gradient component (ΔΨ) of the proton motive
force (PMF), and the correct proton cost of making ATP
by the mitochondrial ATP synthase in animals [14]. It is
also sometimes questionable whether the enormous size
and complexity of these genome-scale models benefits
simulations where only subsystems of cellular metabol-
ism are of interest, such as central metabolism. Further-
more, the scale of genome-scale models can make some
techniques computationally infeasible, such as elemen-
tary mode analysis [15], and the longer runtimes for
their simulations and the complexity of the results can
hinder exploratory analyses and hypothesis testing.
Many problems of genome-scale models can be avoided
by using smaller, curated models validated against data
from normal and disease metabolism. A more focussed
and carefully defined model allows the user to examine
and be confident in each reaction, and more clearly
elucidate the behaviour of the system, including any short-
comings, as well as interpret the results more easily. These
‘core’ models have been shown to be useful in a range of
areas [16, 17] and we previously applied this approach for
our iAS253 model of the mitochondrion, which we used
to simulate metabolic diseases of the tricarboxylic acid
cycle [18]. This model was then used as a basis to simulate
other disorders including hypoxia during cardiac ischemia
[19], fumarate hydratase deficiency [20] and common
diseases of the mitochondrial electron transport chain
[21]. These simulation results were used to generate
detailed mechanistic hypotheses for data interpret-
ation and to design further experiments. However,
we recognised that this model could be improved
upon by constructing a new model encompassing
more of central metabolism and explicitly modelling
physiochemical features such as the mitochondrial
proton motive force. In particular, ease-of-use could
be improved by providing extensive annotation of
reactions and their parameters.
Here we present MitoCore, a new constraint-based
model of central metabolism that addresses these issues
and comprehensively expands upon and refines our
previous mitochondrial models. This model has been
designed to be easy-to-use, includes extensive annotation,
has default parameters to simulate human cardiomyocyte
metabolism, and is encoded in the widely used SBML
format [22]. We anticipate the model will be of great use to
those wishing to interpret empirical data by comparing it to
simulations of central metabolism and thus investigate
predictive models of disease and toxicology.
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Results
Building the MitoCore model of human central metabolism
We designed MitoCore as a constraint-based model of
central metabolism with two compartments; one
representing the cytosol, outer mitochondrial membrane,
inter-membrane space and cytosolic side of the inner
mitochondrial membrane, and the other the mitochon-
drial side of the inner membrane and the mitochondrial
matrix. The accuracy and utility of a metabolic model is
dependent upon the reactions included and the correct
partitioning of these reactions between compartments.
Thus to create MitoCore, we built a list of candidate
reactions to include by considering human reactions in
the KEGG [23], HumanCyc [24] and BRENDA [25]
databases that use any metabolites involved in central
metabolism, and assigned each reaction to the appropriate
cellular compartment(s) by assessing the localisation
evidence collated in the MitoMiner database [26] for its
catalysing protein. For reactions catalysed by enzymes
with a large amount of evidence for mitochondrial
localisation but lacking specific evidence for being in the
mitochondrial matrix or matrix side of the inner
membrane, we applied the principle of metabolite
availability [18]. A summary of this localisation evidence is
provided in the mitochondrial evidence section of the
supplementary annotation file (Additional file 1, ‘Reaction
& Fluxes’ worksheet) and consists of confidence scores
from the MitoCarta 2 [27] inventory of genes that encode
mitochondrial proteins. Reaction directionality was
assigned by taking the consensus from annotation in
metabolic databases, estimates of Gibbs free energy [28,
29], and general rules of irreversibility [30]. For each
reaction extensive additional annotation was recorded
including the original KEGG identifiers, EC number,
description, gene mappings (both HUGO gene symbol
and Ensembl identifiers), and evidence for the gene’s ex-
pression in heart and the protein’s mitochondrial
localisation.
The partitioning of metabolism between the mito-
chondrion and the cytosol logically led us to consider
how to model the proton motive force (PMF) and the
role of protons crossing the inner mitochondrial
membrane as part of oxidative phosphorylation, which
produces the majority of cellular ATP. The PMF is
achieved by complexes I, III and IV pumping matrix
protons across the mitochondrial inner membrane and
into the intermembrane space. This proton-pumping
creates a proton motive force (PMF) across the mem-
brane that has two components: a proton gradient
(ΔpH) coupled with an electrical membrane potential
(ΔΨ). The energy for proton-pumping comes from the
transfer of electrons down the respiratory chain from
NADH and ubiquinone to oxygen, to form water. Add-
itional electrons are passed into the respiratory chain
from the TCA cycle by complex II, and from the degrad-
ation of fatty acids and amino acids by the electron-
transfer flavoprotein (ETF). Mitochondrial ATP synthase
uses the PMF to power ATP synthesis from ADP and
phosphate by channelling protons back across the inner
mitochondrial membrane. It is thus clear that it is neces-
sary to distinguish as Peter Mitchell did [31], the protons
involved in chemical reactions taking place in an isolated
compartment (“scalar protons”), from the protons cross-
ing between compartments (“vectorial protons”). There-
fore, to represent the PMF and distinguish between
scalar and vectorial protons, we modeled the PMF in
MitoCore as a metabolite that is co-transported in steps
that transport charged metabolites or protons across the
inner mitochondrial membrane. We accounted for the
relative contributions of both ΔΨ and ΔpH to the over-
all PMF by co-transporting 0.82 PMF metabolites for
transport steps that affect ΔΨ, and 0.18 PMF metabolites
for transport steps that affect ΔpH. These values are the
average of published figures of the relative contributions
of ΔpH and ΔΨ by several authors (see Additional file 2
for details and references). Therefore, the reactions that
represent complexes I, III and IV of the respiratory
chain move PMF metabolites that correspond to the
number of protons they pump from the matrix to the
cytosol, as a proton in this case affects both ΔΨ and
ΔpH. For example mitochondrial ATP synthase needs to
transport 2.7 PMF metabolites back to the matrix to
synthesise one molecule of ATP (as it uses 2.7 protons
per molecule of ATP [14]). We modelled electrogenic
and proton-coupled transport steps between the two
compartments in the same way; for example the
mitochondrial ATP/ADP carrier 1 (SLC25A4) requires
0.82 PMF to be co-transported with each imported
ADP3− and exported ATP4− nucleotides to reflect the
charge difference that affects only ΔΨ (Eq. 1), whereas
the proton-coupled phosphate carrier (SLC25A3)
imports 0.18 PMF as overall transport is electro-neutral
and so only affects ΔpH (Eq. 2):
ATPmito þ ADPcytosolic
þ 0:82 PMFcytosolic➔ATPcytosolic þ ADPmito
þ 0:82 PMFmito ð1Þ
Hþcytosolic þ 0:18 PMFcytosolic
þ Picytosolic ➔Hþmito þ 0:18 PMFmito þ Pimito ð2Þ
We next modelled the remaining transport steps that
connect the compartments, and the influx and efflux of
metabolites to the cytoplasm. We defined four different
transport categories. First were transport steps based on
the characterised mitochondrial transport proteins.
Many carriers can transport a range of related substrates
(although with different affinities) and we modelled each
metabolite combination as a separate step including
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counter exchange and proton-coupling. In some cases
proton-coupled transporters were represented by two
reactions to model separately the forward and reverse
directions, and a proton (plus co-transported PMF
metabolite) only used for movement down the proton
gradient. This prevented transporters being used in re-
verse to pump protons artificially (and so transferring
PMF) and thereby unrealistically contributing to ATP
production by the mitochondrial ATP synthase. The
second category was for metabolites whose transporters
are unidentified. We modelled these steps as uniporters
that are not proton coupled. If the metabolite was
charged and moving into the mitochondrial matrix we
assumed this would impact ΔΨ and co-transported 0.82
PMF metabolite accordingly. The third category was for
metabolites that can diffuse across the inner mitochon-
drial membrane—including oxygen, carbon dioxide and
water—and these were modelled as reversible uniport
transport steps. Finally we modelled the insertion of
lipids into the mitochondrial inner membrane via the
flippases, which was coupled to ATP hydrolysis.
To account for the generation of reactive oxygen
species (ROS) from the respiratory chain in MitoCore,
we defined their production as 0.001% of the flux
through complex I—the primary site of ROS generation
from the respiratory chain—and hence also reduce the
efficiency of proton-pumping [32, 33]. Subsequent
reactions model ROS being converted to water at the
expense of NADPH.
Various reactions defined in KEGG do not distinguish
between free and prosthetic redox cofactors, e.g. FAD/
FADH, which can lead to unrealistic electron transport
being mediated between prosthetic redox co-factors. To
prevent this in MitoCore, we removed prosthetic co-
factors from reactions (such as for complex II and the
ETF), and instead directly coupled their reactions, e.g. to
the reduction of ubiquinone to ubiquinol.
For convenience in setting up simulations, we created
four ‘pseudo’ reactions that summarise aspects of
MitoCore’s biological activity and can be used by flux
balance analysis as objective functions: ATP hydrolysis
(representing cellular ATP demand), and the biosynthesis
of heme, lipids and amino acids.
To enable comparison of results from MitoCore to those
of genome-scale models such as Recon 2 [5], we re-used
identifiers for metabolites and reactions present in the
Virtual Metabolic Human database (https://vmh.uni.lu) for
MitoCore where possible. However, it was necessary to
create 105 new reactions for MitoCore (Additional file 3)
that were either absent from the Virtual Metabolic Human
database and Recon 2.2 [10] (such as transport steps or
compartment specific versions), inaccurately described
(such as specifying prosthetic FAD as a free co-factor), or
needed to represent new features (such as the proton
motive force). New reaction identifiers were appended with
the suffix ‘MitoCore’. Pathways represented in MitoCore
include glycolysis, pentose phosphate pathway, TCA cycle,
electron transport chain, synthesis and oxidation of fatty
acids, ketone body and amino acid degradation and cover
all parts of central metabolism involved directly or
indirectly with ATP production. Finally, MitoCore was
extensively tested to ensure: it contained no erroneous
energy-generating cycles; its simulation results were
consistent with disorders we investigated previously, such
as ischemia and mitochondrial diseases [18–21]; each
reaction was capable of having a flux (depending on the
constraints placed on the cytosolic boundary transport
steps) and so ensure it contained no reaction dead-ends.
To enable others to follow our reasoning for assigning
reactions to specific compartments and their directionality,
we recorded the provenance for reactions (Additional file 1).
For example, the directionality evidence section describes
why a constraint has been set; a manually evaluated
consensus of information from the KEGG [23], HumanCyc
[24] and BRENDA [25] databases, general rules of irreversi-
bility [30], large ΔG values from eQuilibrator [29] or
estimated using a group contribution method [28], and
information from the literature. In cases for which reaction
directionality was unclear, it was kept reversible. To address
why a reaction has been included in our cardiomyocyte
model, we included a heart expression section consisting of
RNAseq and immunochemistry expression levels of genes
taken from the Human Protein Atlas (version 14) [9]. The
spreadsheet also includes gene mappings, identifiers from
Recon 2 and KEGG, mitochondrial localisation evidence
(as described above) and baseline reaction fluxes when the
objective function was maximum ATP production under
normal conditions. For distribution, we encoded MitoCore
in SBML [22] (Additional file 4) and produced a compan-
ion annotation Excel spreadsheet (Additional file 1).
Simulating cardiomyocyte metabolism using MitoCore
and flux balance analysis
MitoCore’s default reactions and parameters are optimised
for cardiomyocytes and use the metabolites available to
healthy hearts of glucose, fatty acids, ketone bodies and
amino acids (references listed in Additional file 1). To
demonstrate MitoCore’s capability of producing physio-
logical relevant results using these parameters, we simu-
lated cardiomyocyte metabolism by using flux balance
analysis (FBA) [3]. To reflect the primary role of central
metabolism in cardiomyocytes we set the simulation’s
objective as maximum ATP production and calculated the
optimum reaction fluxes through central metabolism. The
resultant reaction fluxes simulated core metabolism
correctly with activity of all respiratory complexes, the TCA
cycle and malate-aspartate shuttle (Fig. 1, Additional file 1).
As metabolic fuels were provided in slight excess, the
Smith et al. BMC Systems Biology  (2017) 11:114 Page 4 of 13
availability of oxygen limited the overall fluxes. Simulated
ATP production was 100.9 μmol/min/g of dry weight.
Sources of acetyl-CoA for the TCA cycle were fatty acid
degradation (55.0%), glucose oxidation (26.4%), lactate
oxidation (8.4%), ketone body degradation (6.1%), amino
acid degradation (3.8%) and glycerol oxidation (0.3%). The
amino acids degraded and used to produce ATP were
histidine, isoleucine, leucine, lysine, threonine, valine,
arginine, aspartate, cysteine, glycine, proline, serine, aspara-
gine, and alanine. Ammonia, produced as a by-product of
amino acid degradation, was exported from the system. To
determine the robustness of the FBA simulation results
with these parameters, we performed Flux Variable Analysis
(FVA) at 100% and 98% of the optimal solution (See
Methods and Additional file 1).
Metabolite degradation and ATP yields with MitoCore
and Recon 2.2
To demonstrate how different metabolites are degraded
appropriately in the MitoCore model and the effect on
ATP production of implementing the proton motive
force, we performed a series of simulations using
particular ‘fuel’ metabolites in isolation. We simulated
the oxidation and degradation of glucose, lactate,
hexadecanoic acid, hydroxybutanoate, acetoacetate and
20 different amino acids in separate simulations
(Additional file 5). The simulations showed that in each
case the degradation routes used were biologically
plausible. Unsurprisingly fatty acids were the most
energy rich fuels (ATP production of 112 μmol/min/g of
dry weight), followed by the amino acids tryptophan
(43 μmol/min/g of dry weight), isoleucine (38 μmol/
min/g of dry weight), leucine (37 μmol/min/g of dry
weight) and phenylalanine (36 μmol/min/g of dry
weight) and then glucose (33 μmol/min/g of dry weight).
To compare the simulations by MitoCore with those
from a genome-scale model, we performed the same
metabolite degradation and ATP yield simulations with
the human genome-scale model Recon 2.2 [10] (Table 1).
The Recon 2.2 model used biological plausible routes in
the degradation of many metabolites, such as histidine,
isoleucine, leucine, lysine, phenylalanine, threonine, tryp-
tophan, valine, arginine, cysteine, glutamate, glutamine,
glycine, and tyrosine. However, non-canonical pathways
Fig. 1 Summary of the major active pathways of central metabolism in the flux balance analysis simulation of the MitoCore model with default
parameters and the objective function of maximum ATP production. Values of all fluxes are reported in Additional file 1.
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were used with several other metabolites. For example,
in glucose metabolism, Recon 2.2 produced lactate from
pyruvate, transported this lactate into the mitochondrion
and then converted it back to pyruvate, bypassing both
the pyruvate carrier and the malate-aspartate shuttle.
Lactate degradation followed a similar route. For fatty
acid degradation, the Recon 2.2 simulation used sum-
mary reactions for β-oxidation (instead of the individual
degradation steps that are also present in the model)
that have FADH as a cofactor. The electrons from this
FADH then incorrectly entered the electron transport
chain via the prosthetic FADH of one of the reactions
representing mitochondrial succinate dehydrogenase
(SDH), also resulting in the two reactions representing
the activity of the SDH complex not having the same
flux. In addition, the carnitine shuttle was inactive in
Recon 2.2 simulations. In some cases, the degradation of
particular amino acids used reactions that are unlikely to
be present in humans, such as 3-hydroxypropionate de-
hydrogenase (EC 1.1.1.59, Recon 2.2 reaction ID: r0365)
used in methionine degradation, or used a reaction in
a direction that is unlikely in vivo, such as for
pyrroline-5-carboxylate reductase 1 (EC 1.5.1.2, Recon
2.2 reaction ID: PRO1xm) in proline degradation.
Simulating the mitochondrial disease fumarase deficiency
with MitoCore and Recon 2.2
To compare the ability MitoCore and Recon 2.2 to model
diseases of central metabolism, we performed preliminary
simulations of the mitochondrial disease fumarase defi-
ciency (OMIM:606812). Fumarate deficiency is a mito-
chondrial disease resulting from a defect in the fumarate
hydratase gene (ENSG00000091483) that encodes both
cytosolic and mitochondrial isoforms, and that converts
fumarate to malate—a key step in the TCA cycle. This can
leave patients with almost no residual enzyme activity and
causes developmental delay, severe mental retardation,
seizures and dysmorphic facial features [34–37]. A key
diagnostic marker for the disease is the presence of fumar-
ate in the cerebrospinal fluid.
To simulate the disease in each model we used the
default cardiomyocyte uptake parameters of MitoCore
Table 1 Comparison of maximum ATP yields from different carbon source ‘fuel’ metabolites
Metabolite MitoCore ATP Yield Recon 2.2 ATP Yield
Glucose 33.0 32.0
Fatty acid hexadecanoate (C16) 111.8 106.8
Lactate 15.5 15.0
Hydroxybutanoate 23.1 20.3
Acetoacetate 20.2 18.0
Histidine 26.3 25.5
Isoleucine 37.8 35.5
Leucine 37.1 33.5
Lysine 36.2 32.0
Methionine 18.3 27.0
Phenylalanine 36.2 33.0
Threonine 20.1 19.0
Tryptophan 43.1 39.5
Valine 30.1 29.0
Arginine 29.2 27.5
Aspartate 16.0 15.0
Cysteine 16.1 17.5
Glutamate 23.8 22.5
Glutamine 24.0 22.5
Glycine 8.0 8.0
Proline 28.1 27.5
Serine 13.1 13.5
Tyrosine 38.9 35.5
Asparagine 16.0 15.0
Alanine 16.0 15.0
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(replicating them in Recon 2.2) and inactivated both
the cytosolic and mitochondrial reactions that
represent the enzyme. The MitoCore model showed a
72% reduction in ATP production upon deletion of
fumarate hydratase compared to the default model
(Fig. 2, Additional file 6). Flux through the TCA cycle
continued at a lower level until reaching fumarate,
which was effluxed. To bridge the break in the TCA
cycle due to the inactive fumarate hydratase and
allow the TCA cycle to complete, oxaloacetate was
produced from pyruvate (by using mitochondrial
pyruvate carboxylase) and the malate-aspartate shuttle
and fed into the TCA cycle. Amino acid degradation
further bolstered flux through the TCA cycle. All
these compensatory reactions seemed biologically
plausible. In contrast, Recon 2.2 showed a much
lower drop in ATP production of 17% upon inactiva-
tion of fumarate hydratase activity. This was largely
due to compensation by a reaction that represents cit-
rate (pro-3S)-lyase (Recon 2.2 reaction ID:CITL, EC:
4.1.3.6) that allowed the degradation of fatty acids
and ketone bodies to continue at a higher rate than
was possible in the MitoCore model by converting
citrate to oxaloacetate and acetate, which was
effluxed. However, citrate (pro-3S)-lyase is absent
from humans and the gene assigned to this reaction
in the Recon 2.2 model has been characterised to con-
vert glyoxylate and acetyl-CoA to malate [38].
The effect of proton leak on the electron transport chain
in MitoCore
To show the MitoCore model can simulate experi-
mentally induced conditions that are directly affected
by the proton motive force, we performed a series of
simulations representing an increasing proton leak
across the mitochondrial inner membrane. We
introduced a flux through the transport step that
represents the leak of matrix protons to the cytosol
through the uncoupling protein 2 (UCP2) in
cardiomyocytes [39]. The optimum reaction fluxes
for maximum ATP production (Additional file 7)
were identical to those under default constraints
with the exception of the steps involved in mito-
chondrial ATP synthesis. Maximum ATP production
was reduced as the proton leak increased due to the
progressively reduced flux through mitochondrial
ATP synthase until it reversed under very high leak
(Fig. 3), and used ATP synthesized in the TCA cycle.
At the highest level of proton leak the flux also re-
versed through the mitochondrial ATP/ADP carrier
and the phosphate carrier to import additional ATP
from glycolysis.
Discussion
Here we present MitoCore, a curated, constraint-based
model of human central metabolism, designed as a pre-
dictive model of metabolism in disease and toxicology,
Fig. 2 Summary of the compensatory pathways used by the MitoCore and Recon 2.2 models when simulating fumarase deficiency with the
objective function of maximum ATP. (Red arrows represent reactions active in both models; purple arrows are only active in the MitoCore model;
and orange arrows are only active in the Recon 2.2 model)
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and for use by a wide range of researchers. It covers all
major pathways involved in central metabolism using
407 reactions and mitochondrial transport steps, and 74
transport steps over the plasma membrane. To increase
the metabolic flexibility of MitoCore, we included a large
number of reactions that were not assigned to classical
metabolic pathways, but could have potentially import-
ant roles in supporting central metabolism. MitoCore
was parameterised and annotated for cardiomyocyte
metabolism, which is useful for many types of analyses
as the cardiomyocyte can metabolise a wide range of
substrates and has reactions common to many other cell
types, as well as representing the metabolism of an
organ of utmost importance in human health, disease
and toxicology. This allows the simulation results to be
generalisable, without having features that are particu-
larly cell specific, such as those found only in hepato-
cytes. However, we have included reactions that are
inactivated in the default cardiac model, but can be acti-
vated to represent the metabolic capabilities of other cell
types, e.g. gluconeogenesis, ketogenesis, β-alanine
synthesis and folate degradation. Thus, the model allows
biologically relevant flux distributions to be generated
‘out of the box’ without altering the model, while allow-
ing for easy modification to represent metabolism in
other cell types.
MitoCore has several unique features. The first is the
more accurate partitioning of metabolism between the
mitochondrion and the cytosol by using extensive local-
isation data and annotation. This partitioning has an im-
portant impact on model behaviour as the limited
transport steps into the mitochondrial matrix result in
dramatic differences in metabolite availability in the
matrix compared to the cytosol. Therefore, it is import-
ant that reactions are assigned to the correct compart-
ment. We achieved this by manually evaluating the
subcellular localisation of each reaction’s catalysing pro-
tein by using the mitochondrial localisation evidence in
the MitoMiner database [26].
To model oxidative phosphorylation in MitoCore, we
devised a new representation of the PMF and mitochon-
drial respiratory chain—the second unique feature of
MitoCore. MitoCore’s representation of the respiratory
chain differs in many key aspects to other metabolic
models, due to how it models vectorial protons and
accounts for both components of the PMF. MitoCore
represents the PMF as a metabolite that is co-
transported in steps that transport charged metabolites
or protons across the inner mitochondrial membrane,
such as the reactions of the respiratory complexes, and
in proton-coupled and electrogenic transport steps. This
separate modelling of vectorial protons using an add-
itional new PMF metabolite enabled the impact of elec-
trogenic transporters on the PMF to be accounted for in
flux balance analysis simulations for the first time, and
prevented simulation artefacts where (scalar) protons
generated or removed from other parts of metabolism
allow unrealistically high ATP production.
The third unique feature of MitoCore is the physio-
chemical modelling of the transport steps that connect
the cytosolic and mitochondrial compartments including
their impact on the PMF, and the influx and efflux of
metabolites over the plasma membrane. 83 transport
steps connect the two compartments, of which 30 are
modelled on the known transport mechanisms of char-
acterised transport proteins of the inner mitochondrial
membrane, whereas the other 53 represent known trans-
port capabilities of the membrane, such as diffusion of
small metabolites. 74 transport steps at the cytosolic
boundary represent the import and export of metabolites
across the plasma membrane, such as oxygen, carbon
dioxide, glucose, fatty acids and amino acids.
MitoCore improves over other models by distin-
guishing between free and prosthetic redox co-factors.
This keeps separate the electrons entering the respira-
tory chain from different sources, which can other-
wise become connected via e.g. a shared flavin
adenine nucleotide metabolite, and is particularly
relevant under perturbed conditions where the erro-
neous connection of free and prosthetic flavin adenine
nucleotides can cause unrealistic electron transport
bypasses to occur. This problem is endemic in large-
scale models that auto-generate reaction networks
directly from metabolic databases without manual
curation of reactions.
Other improvements to MitoCore included modelling
protein complexes as one reaction rather than a series of
Fig. 3 The effect of increasing proton leak through UCP2 during
simulations of the MitoCore model on: maximum ATP production, flux
through mitochondrial ATP synthase, flux through the mitochondrial
ATP/ADP transporter, and flux through the mitochondrial phosphate
transporter. The flux through ATP synthase is distinct from all the other
fluxes that are superimposed, because there is also synthesis of
mitochondrial ATP from the TCA cycle
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linked reactions, as can often be found in metabolic
pathway databases and other models. This is particularly
important for simulations of gene knockouts, as a gene
deficiency will disrupt the activity of the whole protein
complex rather than just one of its subunit’s reactions.
Further, to facilitate gene-based analyses (such as knock
out studies) we provide reaction-to-gene mappings with
both gene symbols and Ensembl identifiers. Finally, to
summarise different aspects of central metabolism dur-
ing simulations with MitoCore, we defined four ‘pseudo’
reactions for biosynthesis of amino acids, lipids and heme
that are required by cells for maintenance and growth,
and ATP hydrolysis to reflect the energy demand of the
cell. These pseudo reactions are designed to be used as
objective functions during flux balance analysis and can
determine if particular functions of central metabolism
have become impaired during simulations of disease.
A weakness when it comes to interpreting many
metabolic models is the lack of provenance about their
components. For example recording why reactions have
been included, why directionality constraints have been
set, or the origin of reaction parameters. Thus for Mito-
Core we created a supplementary annotation spread-
sheet (Additional file 1) to record this provenance. The
spreadsheet also serves as a useful template to map flux
distributions onto, as reaction fluxes can be grouped in
an intuitive way directly against useful supplementary
information. When combined with the small size of the
model, simulations can be generated quickly and then
easily interpreted.
To demonstrate that MitoCore produces physiologic-
ally realistic results, we simulated cardiomyocyte metab-
olism using the default parameters with flux balance
analysis [3] and the objective of maximum ATP produc-
tion. The reaction fluxes showed central metabolism was
modelled correctly, with the largest fluxes through the
TCA cycle and respiratory chain. Numerous fuel sources
(fatty acids, glucose, lactate, ketone bodies and amino
acids) were imported, degraded and entered the TCA
cycle at several different points (Fig. 1). The combin-
ation of different fuel metabolites used in the simula-
tions showed similar trends to experimental ranges in
well-perfused heart (although the reported ranges are
large, reflecting the wide range of metabolites that the
heart can potentially use). For example, experimental
measurements of the sources of acetyl-CoA for the TCA
cycle [40] report the majority of acetyl-CoA (60–90%)
derives from fatty acids, which is close to the 55% in the
MitoCore simulation, whereas glycolysis (including lac-
tate oxidation) accounts for 10–40% of acetyl-CoA com-
pared to 35% in the MitoCore simulation, with the
remainder of acetyl-CoA derived from amino acids.
Finally, to show the robustness of the simulation results,
we performed Flux Variability Analysis (FVA). The
ranges for reaction fluxes calculated (Additional file 1)
showed a realistic range of values and a lack of flux
loops (apart from interrelated mitochondrial transport
steps), with most of the fluxes uniquely determined or
having a limited range with large non-fixed fluxes corre-
sponding to isoenzymes or transport steps whose fluxes
exchange while maintaining a fixed total flux.
To show the importance of explicitly modelling the
PMF, we simulated the maximum ATP production
achievable using 1 μmol/min/g of dry weight of common
metabolic fuels in isolation (effectively calculating their
ATP yields) and compared the results to those generated
by the genome-scale model Recon 2.2 [10] and from the-
oretical calculations [41] (Table 1 and Additional file 5).
Recon 2.2 is an update of the widely used Recon 2
model [5], which also separates protons used by the
electron transport chain and the aspartate-glutamate
carrier from the rest of metabolism to allow it to predict
ATP yields, unlike its predecessor, Recon 2, that
produces infinite ATP under these conditions [10].
However, Recon 2.2 does not directly capture the
energetic cost on ATP production of other proton
coupled mitochondrial transport steps or the ΔΨ part of
the PMF. In MitoCore each glucose produced 33 ATP in
comparison to 32 calculated theoretically [41] and 32 in
Recon 2.2 [10]. For the fatty acid hexadecanonic acid
112 ATP were produced compared to 108 theoretically
[41] and 107 in Recon 2.2. A significant difference
between the models is the number of protons required
by mitochondrial ATP synthase to produce one molecule
of ATP: MitoCore uses 2.7 (based on the structure of
the bovine mitochondrial ATP synthase [14]) whereas
the theoretical calculations use 2.5 and Recon 2.2 uses
4.0 (presumably to account indirectly for the electroneu-
tral proton-coupled phosphate carrier and electrogenic
charge-coupled ATP/ADP exchange). Due to also
considering additional factors that affect ATP productio-
n—including the impact and bioenergetic cost of all the
transport steps on the PMF as well as ROS production
and removal—we believe our figure is likely to be more
accurate than both Recon 2.2 and these theoretical
calculations. When comparing the flux distributions
between MitoCore and Recon 2.2 it appears that despite
having similar ATP yields for many metabolites, the
pathways used by MitoCore are more biologically
reasonable for some metabolites (i.e. using canonical
degradation pathways) and lacked some of the unlikely
elements found in Recon 2.2, such as using a lactate
shuttle instead of the pyruvate carrier during glucose
oxidation. In some Recon 2.2 simulations the malate-
aspartate shuttle was inactive, presumably due to its use
having a direct penalty on ATP production, the only
transport step defined in Recon 2.2 to do so. MitoCore
avoids this problem of unrealistic bypasses by using
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PMF penalties on all the relevant mitochondrial
transport steps.
Further differences could be seen when comparing the
results of preliminary simulations of fumarase deficiency
(Fig. 2) that showed MitoCore replicating the efflux of
fumarate seen in patients while also using plausible
compensatory mechanisms, which would provide a prom-
ising starting point for further simulations and analysis
(such as determining the effect of varying parameters).
Recon 2.2 did not replicate the efflux of fumarate, and
ATP production was maintained by using a reaction
(CITL, a non-ATP dependent citrate lyase) that instead
effluxed acetate. This reaction is unlikely to be present in
human, which suggests the Recon 2.2 model would
require further investigation and changes to simulate
fumarase deficiency realistically.
An important aspect of modelling is exploring different
hypotheses by running multiple simulations with different
parameters. This is especially true when simulating mech-
anisms of disease, which may reveal compensatory mecha-
nisms and the effect of supplying different metabolites to
compensate for metabolite deficiencies. Therefore, it is
beneficial if simulation runtimes are comparatively short.
Even when using computationally expensive types of flux
balance analysis, such as geometric FBA, MitoCore takes
~10 s per run, compared to ~3 h per run for Recon 2.2.
The short runtime for MitoCore simulations makes the
exploration of varying parameters much easier and rou-
tine, computationally expensive methods feasible, and al-
lows rapid testing of new ideas and hypotheses.
When comparing maximum ATP production using de-
fault parameters to the previous iAS253 model using the
same parameters [18], ATP production was notably lower
(101 vs 140 μmol/min/g of dry weight) due to the intro-
duction of PMF metabolites in the electron transport
chain and transport steps, demonstrating it has an import-
ant effect. The results from the proton leak simulations
(Additional file 7) show the use of metabolites to represent
the PMF enables the model to replicate experimental ob-
servations under perturbed conditions that would other-
wise be impossible, such as the reversal of mitochondrial
ATP synthase, the ATP/ADP carrier and the phosphate
carrier. Such behaviour is well-known in the absence of
respiratory chain activity, for instance in ρ0 cells to main-
tain a proton motive force in mitochondria [42, 43].
Taken together these simulation results show the
MitoCore model is capable of producing realistic results
using a wide range of metabolites while avoiding some of
the common problems of genome-scale models, including:
unlikely shuttling between compartments, reactions that
are not compartmentalized correctly, incorrect direction-
ality constraints and the inclusion of reactions that are
unlikely to be present in human. These problems, while
understandable due to the scale of these models,
nevertheless make producing biological relevant flux dis-
tributions difficult, especially under perturbed conditions,
and show the continued need for carefully curated ‘core’
models for some types of simulation. Further, these com-
parisons illustrate an additional role for ‘core’ models,
which is the ability to identify and diagnose problem areas
for improvement in genome-scale models.
Conclusions
MitoCore is a constraint-based model of human central
metabolism, provided with default parameters that
provide physiologically realistic reaction fluxes for cardi-
omyocytes in FBA simulations. The model has several
innovations including a new representation of the
respiratory chain and proton motive force, and partition-
ing of reactions to subcellular compartments based on
the latest localisation evidence. To achieve an accurate
depiction of central metabolism, each of MitoCore’s 407
reactions and transport steps was manually evaluated for
directionality, expression of its gene in heart, and subcel-
lular localisation of its protein. To allow MitoCore to be
easily used and to make the results comparable with
other models and compatible with other types of
analyses, we used identifiers from the Virtual Metabolic
Human database for both reactions and metabolites
where possible, and recorded KEGG identifiers in the
annotation. To help ease of use, we also provide an
annotation spreadsheet that provides gene mappings,
localisation and heart expression evidence, and notes on
parameter choice. MitoCore is provided in SBML format
to be compatible with a wide range of software. We
hope MitoCore will be of use as a research tool to a wide
range of biomedical scientists and students—from expe-
rienced modellers interested in central metabolism or
using computationally intensive methods that are infeas-
ible on a genome-scale model, to those new to modelling
who would like to begin by using a small manageable
model, with application as a predictive model of disease.
Methods
Identifying reactions of central metabolism to include in
MitoCore
The starting point for the MitoCore model was an up-
dated version of the iAS253 mitochondrial model [21].
The model was expanded by searching for human
reactions in KEGG [23], HumanCyc [24] and BRENDA
[25] that were missing from the iAS253 model and could
impact central metabolism. Each reaction was reassessed
for subcellular localisation and directionality (see below),
and to ensure the reactions were occurring in most
tissues including cardiac, tissue expression of their
genes and proteins was verified by using the Human
Protein Atlas [9].
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Partitioning reactions between the cytosol and
mitochondrion in MitoCore
To partition the reactions into either the cytosol or
mitochondrion, each enzyme was manually evaluated by
using the mitochondrial localisation evidence in the Mito-
Miner database [26]. MitoMiner collates GFP tagging,
large-scale mass-spectrometry mitochondrial proteomics
studies and mitochondrial targeting sequence predictions,
with detailed annotation from the Gene Ontology and
metabolic pathway data from KEGG. MitoMiner also
contains homology information allowing localisation
evidence to be shared amongst species. All available
experimental localisation evidence, mitochondrial target-
ing sequence predictions and annotation were considered,
including from homologs from mouse, rat and yeasts. For
reactions with strong evidence for mitochondrial localisa-
tion, but where matrix localisation is unclear, the principal
of metabolite availability was applied —a reaction can only
be present in a compartment if all its substrates are avail-
able and its products can be used by reactions within the
same compartment [18]. Reactions residing in the mito-
chondrial matrix or matrix side of the mitochondrial inner
membrane were assigned to the mitochondrial compart-
ment. Transport steps were created to connect the cytosol
and matrix based on the transport properties of the mem-
brane (active transport, diffusion, etc.). Each reaction was
cross-referenced with the Virtual Metabolic Human data-
base (https://vmh.uni.lu) and used its identifiers for reac-
tions and metabolites where possible.
Assigning reaction directionality in MitoCore
Reaction directionality was manually evaluated for
each reaction in MitoCore. The KEGG [23], Human-
Cyc [24] and BRENDA [25] databases were con-
sulted, and general rules of irreversibility were taken
into account (such as most reactions consume ATP
rather than produce it and carbon dioxide is nor-
mally produced not consumed) [30]. The ΔG values
for reactions were also considered, both calculated
by eQuilibrator [29] and estimated by using the
group contribution method [28], and large changes
noted. If reaction directionality was conflicted or un-
clear, then the literature was consulted. If support
for irreversibility was poor or a consensus could not
be found, the reaction was assigned reversible. The
information used to make each assessment was
recorded in the directionality evidence column of
the annotation spreadsheet (Additional file 1). Fur-
ther refinement of reaction directionality was used
to eliminate loops that could produce metabolites
such as ATP and NADH for ‘free’, and to prevent
the interconversion of NADH and NADPH, unless it
had been experimentally verified.
Defining and updating reactions in MitoCore
Modelling of the proton motive force (PMF) was
improved across the mitochondrial inner membrane, a
pseudo-metabolite was introduced to model the effect on
the PMF of proton and electrogenic transport steps across
the inner mitochondrial membrane. In total 43 reactions
representing respiratory complexes as well as proton-
coupled transport steps were rewritten to use this new
species. Next, to prevent unrealistic bypasses between free
and complex-bound prosthetic flavin adenine dinucleo-
tides, FADH and FAD+ were removed from all reactions
and replaced with ubiquinone and ubiquinol. Finally, to
represent better the current understanding of central
metabolism pathways, some reactions were rewritten,
such as the generation of ROS from complex I, and the
stoichiometry of the proton-pumping of the respiratory
complexes. In some cases a reaction’s subcellular localisa-
tion was changed by defining mitochondrial-specific
metabolite species, or new reactions were written using
existing metabolite species.
To highlight where there are differences between a
MitoCore reaction and the corresponding reaction in the
Virtual Metabolic Human database, the MitoCore identi-
fier used the Virtual Metabolic Human database identifier
with the suffix ‘MitoCore’. (N.B. Recon 2 also uses The
Virtual Metabolic Human database identifiers.)
Testing the MitoCore model
The model was extensively tested: each reaction in the
model was set as the objective function in a series of
simulations to ensure all reactions were capable of
having flux, with directionality constraints reevaluated
for both the reaction and other members of the same
pathway if this was not the case; erroneous energy-
generating cycles were manually identified and removed
by running a succession of simulations where ATP
production was maximised and a wide range of different
‘fuel’ metabolites provided; that the model used
physiologically characterised pathways under normal
conditions and used plausible mechanisms under
perturbed conditions.
The MitoCore model was encoded in SBML v2.1 and
its validity checked with the SBML online validator [44].
Simulating metabolism
Metabolism was simulated by using flux balance ana-
lysis (FBA), which can be summarised as calculating
the reaction turnover, or fluxes (flows) of metabolites
through a network of biochemical reactions assuming
a pseudo steady state [3]. The fluxes through the net-
work are constrained by the stoichiometry and direc-
tionality of the reactions, as well as flux capacity and
cytosol boundary uptake ranges. Cytosol boundary
transport steps model the import and export of
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metabolites to the cell, but the overall rate of produc-
tion and consumption of metabolites is assumed to
be zero, hence a pseudo steady state. A metabolic
objective function is chosen for each simulation, and
FBA used to calculate an optimal set of reaction
fluxes that maximise this function. For simulations
here, maximum ATP production (by maximising flux
through the pseudo reaction of ATP hydrolysis) was
used as the objective function because energy gener-
ation is a major purpose of central metabolism,
particularly in cardiomyocytes. To determine the
robustness of the model solutions and identify the
most important reactions contributing to the optimal
solution, flux variability analysis (FVA) was used. FVA
calculates the flux ranges of each reaction that still
give the same (maximal) value of the objective
function as the optimal solution, or a fraction of it.
FVA was applied at 100% and 98% of the optimal
ATP production.
For simulations of ATP yield, all cytosol boundary
uptake fluxes for metabolites that can be degraded to
produce ATP were set to zero, oxygen was increased to
50 μmol/min/g of dry weight (so that limited oxygen
availability did not affect results), while other cytosol
boundary conditions were unaltered. The uptake flux of
each metabolite of interest was then increased to
1 μmol/min/g of dry weight. Geometric FBA simulations
were then performed with maximum ATP production as
the objective function. (When Recon 2.2 simulations did
not obtain convergence, the ‘epilson’ and ‘flexRel’ param-
eters were relaxed from the defaults.)
For simulations of fumarase deficiency, the reactions
corresponding to mitochondrial and cytosolic fumarate
hydratase were inactivated in each model, whilst the
uptakes values were left at default values. Simulations
were performed with geometric FBA and an objective
function of maximum ATP production. To enable
geometric FBA of the Recon 2.2 model to converge to a
solution, the efflux was prevented of acetone (Recon 2.2
reaction ID: EX_acetone), tetradecanoate (Recon 2.2
reaction ID: EX_ttdca), 3-(4-hydroxyphenyl)pyruvate
(Recon 2.2 reaction ID: EX_34hpp_), 4-methyl-2-oxopen-
tanoate (Recon 2.2 reaction ID: EX_34hpp_) and
bicarbonate (Recon 2.2 reaction ID: EX_hco3).
For simulations of the effect of proton leak on
maximum ATP production, the lower bound of the reac-
tion representing the gene UCP2 (MitoCore reaction ID:
HtmB_MitoCore) was increased over a series of simula-
tions, thus forcing a minimum flux–representing proton
leak—through the reaction.
FBA simulations were performed by using MATLAB
(Math Works, Inc., Natick, MA) and the COBRA Toolbox
[45], with the linear programming solver GLPK (http://
www.gnu.org/software/glpk).
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